CLRB
Cellectar BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
9
U.S. public peers
Grade Position
In line
vs peer average
CLRB vs peer average
57/100
CLRB vs. peer average (C vs. C)
Grade spread
A 2 · C 2 · D 2 · F 3
Graded peers loaded
Coverage
9 graded
100% of tracked
Peer overview
CATX is the first available peer comparator.
Perspective is a radiopharmaceutical Phase 3 execution comparator, but its lead isotope and indication differ from Cellectar's; it is not a direct valuation peer. [Perspective Q2 update](https://perspectivetherapeutics.com/pr/perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2026-results)
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
CLRB
Cellectar Biosciences
CATX
Perspective Therapeutics
Grade
C
A
Momentum
69
27
Value
57
57
Sentiment
49
79
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Constructive
Grade position vs CATX
CLRB / CATX
Grade Position
In line
CLRB vs. peer average (C vs. C)
57/100
Momentum
69
CLRBValue
57
CATXSentiment
49
CATXRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs CLRB
CATX is the first peer returned for this comparison set.